Stay updated on Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial
Sign up to get notified when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.

Latest updates to the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page
- Check4 days agoChange DetectedThe page version updated from v3.0.1 to v3.0.2. The Back to Top element was removed, with no changes to core content.SummaryDifference0.1%
- Check11 days agoChange DetectedThe page has updated the publication date of a significant clinical trial article from May 8, 2025, to July 1, 2025, and has revised the version number from v3.0.0 to v3.0.1.SummaryDifference0.3%
- Check18 days agoChange DetectedThe web page has been updated to include a new facility name and location, along with a significant publication related to a clinical trial involving pembrolizumab for metastatic triple negative breast cancer. Additionally, the revision number has been updated to v3.0.0.SummaryDifference5%
- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check40 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.0%
- Check48 days agoChange DetectedThe page has been updated to version v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference0.6%
Stay in the know with updates to Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.